Razelle Kurzrock, Founding Director of the Michels Rare Cancers Research Laboratories, shared on X by Adam C Palmer, Assistant Professor, Pharmacology and Computational Medicine at The University of North Carolina at Chapel Hill, adding:
“I am absolutely talking about displacing frontline ‘good’ options for solid tumors.
Solid CAs are not Hodgkin where we cure 95%. For many solids, our ‘good’ options are mutilating surgery +radiation and hard-core chemo, and chances are still high you will be dead in a few years.”
Quoting Adam C Palmer:
“I think Razelle Kurzrock is talking about establishing clinically active options for patients who need them (whether later lines of care, or cancer types with awful 1L options), not displacing existing good options when available.”
Other articles featuring Razelle Kurzrock on OncoDaily.